Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium-177-TGW211
- Development stage
- Unknown
- Lead developer
- Tagworks Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Lutetium-177-TGW211 is an investigational radiopharmaceutical specifically designed to target **human epidermal growth factor receptor 2 (HER2)** on tumor cells. It consists of TGW211, a HER2-targeted monoclonal antibody conjugate labeled with the beta-emitting radionuclide **Lutetium-177**. The agent utilizes a radioimmunoconjugate strategy for both imaging and therapy, delivering radioactivity directly to HER2-overexpressing cancer cells, enabling their selective destruction while minimizing systemic exposure. The approach leverages a "click-cleavable" linker, designed for enhanced tumor uptake and rapid elimination of unwanted circulating radioactivity. Lutetium-177-TGW211 is currently in Phase 0/1 clinical trials for the treatment of HER2-positive tumors, including but not limited to breast cancer. The drug is being developed by Tagworks Pharmaceuticals[11][14][16][17][19].
- Other names
- Trastuzumab-TCO-DOTA
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on lutetium-177-TGW211.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium-177-TGW211.